A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year.AbbVie’s multibillion-dollar bid to acquire Cerevel Therapeutics has hit an unusual snag that could prevent the deal from closing for months.The companies said that, on Feb. 16, they received […]
